Alumis Inc.
ALMS
Kedudukan dalam Saham
#10174
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.41
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$830.25M
Perubahan (1 hari)
4.81%
Perubahan (1 tahun)
182.57%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Sejarah pecahan saham untuk Alumis Inc. (ALMS)
Saham Alumis Inc. (simbol: ALMS) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ALMS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ALMS.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham ALMS yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham ALMS.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
